Antiphospholipid antibodies: update on detection, pathophysiology, and treatment
Antiphospholipid antibodies: update on detection, pathophysiology, and treatment
复制标题
抗磷脂抗体：检测、病理生理学和治疗的最新进展
DOI：
--
复制
发表时间：
2004
影响因子：
3.2
通讯作者：
R. Derksen
中科院分区：
文献类型：
--
作者：
P. D. de Groot;R. Derksen
综述目的抗磷脂综合征是一种非炎症性疾病，其特征是静脉或动脉血栓形成或产科并发症患者血浆中存在抗磷脂抗体。对该综合征的病理学的理解只是初步的，没有医生可以假装治疗是足够的。不可能确定患有该综合征的患者。本文回顾了过去一年取得的实质性和有希望的进展。最近的发现已经清楚，狼疮抗凝剂是检测该综合征的首选方法，针对β 2糖蛋白1的抗体是临床相关的自身抗体。这些抗体能够激活参与止血调节的许多细胞。最新的发展将使它很快就有可能明确定义患者的综合征。这对于理解为什么抗磷脂抗体的存在会导致血栓形成风险增加是绝对必要的。
Purpose of reviewThe antiphospholipid syndrome is a noninflammatory disease characterized by the presence of antiphospholipid antibodies in the plasma of patients with venous or arterial thrombosis or obstetric complications. Understanding of the pathology of the syndrome is only rudimentary and no physician can pretend that treatment is adequate. It is not possible to identify patients with the syndrome for certain. This paper reviews the substantial and promising headway made in the past year. Recent findingsIt has become clear that lupus anticoagulant is the assay of choice to detect the syndrome and that antibodies directed towards β2Glycoprotein 1 are the clinical relevant autoantibodies. These antibodies are able to activate a number of cells involved in the regulation of hemostasis. SummaryThe latest developments will make it soon possible to define patient with the syndrome unambiguously. This is absolutely necessary to understand why the presence of antiphospholipid antibodies cause an increased thrombotic risk.